Biomarker allows for cost-effective throat cancer imaging, study suggests

07/25/2013 | Medscape (free registration)

A study published in the Journal of Clinical Oncology found risk stratification using plasma Epstein-Barr virus DNA levels helps determine the utility of PET/CT for finding metastases in nasopharyngeal carcinoma. Chinese researchers conducted PET/CT imaging plus MRI and a clinical workup with chest X-ray, abdominal ultrasound and skeletal scintigraphy in 583  patients. After the evaluation of findings, researchers recommended only clinical workup for very low-risk patients, a choice between clinical workup or imaging for low-risk patients and PET/CT for intermediate-risk patients. PET/CT led to a change in treatment plans for 16.5% of the intermediate-risk patients.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park